These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 28697759)

  • 1. The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model.
    Hsu YC; Chiu YC; Lin CC; Kuo YY; Hou HA; Tzeng YS; Kao CJ; Chuang PH; Tseng MH; Hsiao TH; Chou WC; Tien HF
    J Hematol Oncol; 2017 Jul; 10(1):139. PubMed ID: 28697759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
    Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T
    J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185
    [No Abstract]   [Full Text] [Related]  

  • 3. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.
    Abdel-Wahab O; Gao J; Adli M; Dey A; Trimarchi T; Chung YR; Kuscu C; Hricik T; Ndiaye-Lobry D; Lafave LM; Koche R; Shih AH; Guryanova OA; Kim E; Li S; Pandey S; Shin JY; Telis L; Liu J; Bhatt PK; Monette S; Zhao X; Mason CE; Park CY; Bernstein BE; Aifantis I; Levine RL
    J Exp Med; 2013 Nov; 210(12):2641-59. PubMed ID: 24218140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
    Takeda R; Asada S; Park SJ; Yokoyama A; Becker HJ; Kanai A; Visconte V; Hershberger C; Hayashi Y; Yonezawa T; Tamura M; Fukushima T; Tanaka Y; Fukuyama T; Matsumoto A; Yamasaki S; Nakai K; Yamazaki S; Inaba T; Shibata T; Inoue D; Honda H; Goyama S; Maciejewski JP; Kitamura T
    Blood; 2020 Oct; 136(14):1670-1684. PubMed ID: 32492700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
    J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.
    Fisher CL; Pineault N; Brookes C; Helgason CD; Ohta H; Bodner C; Hess JL; Humphries RK; Brock HW
    Blood; 2010 Jan; 115(1):38-46. PubMed ID: 19861679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification.
    Uni M; Masamoto Y; Sato T; Kamikubo Y; Arai S; Hara E; Kurokawa M
    Leukemia; 2019 Jan; 33(1):191-204. PubMed ID: 29967380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.
    Wang J; Li Z; He Y; Pan F; Chen S; Rhodes S; Nguyen L; Yuan J; Jiang L; Yang X; Weeks O; Liu Z; Zhou J; Ni H; Cai CL; Xu M; Yang FC
    Blood; 2014 Jan; 123(4):541-53. PubMed ID: 24255920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of ASXL1 mutations in hematological disorders].
    Uni M
    Rinsho Ketsueki; 2019; 60(6):680-690. PubMed ID: 31281161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia.
    D'Altri T; Wilhelmson AS; Schuster MB; Wenzel A; Kalvisa A; Pundhir S; Meldgaard Hansen A; Porse BT
    Haematologica; 2021 Apr; 106(4):1000-1007. PubMed ID: 32381577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of ASXL1 in hematopoiesis and myeloid malignancies.
    Asada S; Fujino T; Goyama S; Kitamura T
    Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of ASXL1 mutation in myeloid malignancies].
    Sheng MY; Zhou Y; Xu MJ; Yang FC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
    Inoue D; Kitaura J; Togami K; Nishimura K; Enomoto Y; Uchida T; Kagiyama Y; Kawabata KC; Nakahara F; Izawa K; Oki T; Maehara A; Isobe M; Tsuchiya A; Harada Y; Harada H; Ochiya T; Aburatani H; Kimura H; Thol F; Heuser M; Levine RL; Abdel-Wahab O; Kitamura T
    J Clin Invest; 2013 Nov; 123(11):4627-40. PubMed ID: 24216483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway.
    Fujino T; Goyama S; Sugiura Y; Inoue D; Asada S; Yamasaki S; Matsumoto A; Yamaguchi K; Isobe Y; Tsuchiya A; Shikata S; Sato N; Morinaga H; Fukuyama T; Tanaka Y; Fukushima T; Takeda R; Yamamoto K; Honda H; Nishimura EK; Furukawa Y; Shibata T; Abdel-Wahab O; Suematsu M; Kitamura T
    Nat Commun; 2021 Mar; 12(1):1826. PubMed ID: 33758188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
    Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC
    Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.
    Kawagoe H; Grosveld GC
    Blood; 2005 Dec; 106(13):4269-77. PubMed ID: 16105979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ASXL1 in hematopoiesis and myeloid diseases.
    Gao X; You X; Droin N; Banaszak LG; Churpek J; Padron E; Geissler K; Solary E; Patnaik MM; Zhang J
    Exp Hematol; 2022 Nov; 115():14-19. PubMed ID: 36183966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knock-out of Hopx disrupts stemness and quiescence of hematopoietic stem cells in mice.
    Lin CC; Yao CY; Hsu YC; Hou HA; Yuan CT; Li YH; Kao CJ; Chuang PH; Chiu YC; Chen Y; Chou WC; Tien HF
    Oncogene; 2020 Jul; 39(28):5112-5123. PubMed ID: 32533098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors.
    Braun TP; Estabrook J; Schonrock Z; Curtiss BM; Darmusey L; Macaraeg J; Enright T; Coblentz C; Callahan R; Yashar W; Taherinasab A; Mohammed H; Coleman DJ; Druker BJ; Demir E; Lusardi TA; Maxson JE
    Leukemia; 2023 Feb; 37(2):478-487. PubMed ID: 36526735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.